Dosing and uses of Ocupress (carteolol ophthalmic)
Adult dosage forms and strengths
ophthalmic solution
- 1%
Chronic Open-Angle Glaucoma & Intraocular Hypertension
Instill 1 gtt in affected eye(s) BId
Pediatric dosage forms and strengths
Not recommended
Ocupress (carteolol ophthalmic) adverse (side) effects
>10%
Burning sensation in eye (25%)
Conjunctival hyperemia (25%)
Excessive tear production (25%)
Eye irritation (25%)
1-10%
Blurred and cloudy vision
Photophobia
Decreased night vision
Ptosis
Ocular signs including blepharoconjunctivitis, abnormal corneal staining, and corneal sensitivity occurred occasionally
Systemic side effects may be similar to systemic beta-blockers (bradycardia, aggravation of CHF, asthma, caution in diabetes as may mask signs of hypolgycemia, nightmares, impotence, tiredness, etc)
Reduction of systemic side effects by putting finger in corner of eye (occluding punctum) or by gentle eyelid closure (without opening & closing lid) for 3 min
Warnings
Contraindications
Asthma, uncompensated CHF, any beta-blocker side effects, hypersensitivity, severe COPD, 2°/3° AV block, cardiogenic shock
Pregnancy and lactation
Pregnancy category: C
Lactation: excretion in milk unknown; use with caution
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Ocupress (carteolol ophthalmic)
Half-Life: 6 hr
Duration: 12 hr
Excretion: urine
Mechanism of action
Beta-adrenergic receptor blocker
